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Abstract
Type 1 diabetes is a condition characterized by a lack of insulin production. This lack
of insulin causes glucose concentration in the blood to increase after meals. In order to
maintain blood glucose levels, diabetics must inject insulin using needles or an insulin
pump. Additionally, the lack of insulin can cause glucose levels to decrease overnight.
This project uses a proportional integral derivative (PID) controller to modify the
rate of insulin and glucagon infusion when glucose levels are increasing or decreasing,
respectively.
A system of 13 differential equations were used to anticipate changes in glucose
concentration as insulin and glucagon were injected. The system was simulated for
virtual patients over a 24-hour time span in order to test its feasibility in human
patients. The PID controller uses the current, past, and anticipated future glucose
levels, respectively, in order to better determine the best course of treatment for the
virtual patient.
One of the many difficulties in medical technology, however, is that everyone is
different. These differences are a result of metabolism and other factors. To account
for this fact the controller is designed to change the gain of the different controller
components in order to better tailor the treatment to each patient.
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1 Introduction
Diabetes is a chronic condition that affects nearly 10% of the US population [1]. Of these,
another 5% of diabetics have Type 1 diabetes which is characterized by the body’s inability
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to properly regulate the concentration of glucose in the blood without the external admin-
istration of insulin [3]. Because of this problem, many researchers have developed models
designed to aid in the treatment of diabetes in a number of situations. These range from
models that replicate the body’s response to large quantities of injections and others which
use stochastic methods to account for outside influences like stress levels [7].
In this project, a model proposed by Resalat et al. will be discussed and used in a treat-
ment algorithm. This model, which uses the biological processes affecting blood glucose, is
a combination of biological mass transport and chemistry [9]. The method by which pa-
tients were generated and the model solved will then be introduced. The treatment, which
involves a PID controller being used to maintain healthy glucose levels, will be detailed.
This treatment is administered both during the day, when glucose tends to increase, and
at night, when glucose decreases. The algorithm accomplishes this by introducing insulin
when the glucose increases and introducing glucagon when the glucose decreases. Finally,
some simulations will be run without the controller, with an early version of the controller,
and with the final controller. After this has been done, the quality of the treatment will be
addressed and compared to other solutions being developed.
2 The Model
A total of 13 coupled ordinary differential equations are used in this model. The majority are
linear while the last two are nonlinear. These equations involve insulin kinetics and dynamics,
carbohydrate absorption, and glucagon kinetics and dynamics. Each set of equations is
discussed in more detail below. Please note the dot notation used below indicates a time
derivative.
2.1 Insulin Kinetics
Three differential equations govern insulin kinetics [6]. The equations are as follows:













This is a mass transport model using two subcutaneous compartments. S1 and S2 are
the masses of insulin in each compartment [mU/kg] 1. I is the concentration of insulin
in the plasma [mU/L], and uI is the rate of insulin infusion [mU/(kg·min)]. The last three
110 mU is equal to one mL.
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parameters, tmax, VI , and ke are the time-to-maximum absorption [min], distribution volume
[L/kg], and elimation rate from the plasma [min−1], respectively. In total, these equations
account for the movement of insulin throughout the body.
2.2 Insulin Dynamics
The insulin dynamics model evaluates how glucose concentrations change as a result of
insulin being present in the plasma. Again, three equations govern this model [6].
Ẋ1 = −ka1X2 + Sf1ka1I
Ẋ2 = −ka2X2 + Sf2ka2I
Ẋ3 = −ka3X3 + Sf3ka3I
(2)
Here, the input variable X1 [min
−1] represents the effect of insulin on glucose distribution,
X2 [min
−1] is the effect of insulin on glucose disposal, and X3 [unitless] is the suppression of
endogenous glucose production (EGP). Similar to before, ka1, ka2, ka3 [min
−1] are the rates
at which insulin is entering a compartment as well as the rate at which the insulin’s effects
are being eliminated, where the compartment corresponds with the relevant X variable.
Finally, the variables Sf1 [mU/(L·min)], Sf2 [mU/(L·min)], and Sf3 [mU/L] represent the
sensitivity of the body to the concentration of insulin.
2.3 Glucagon Kinetics
The absorption rate of subcutaneously injected glucagon into the plasma is represented by
this triad of equations [9]:
Ẋ1g = −(k1g + kge1)X1g + ug
Ẋ2g = k1gX1g − k2gX2g
Ẋ3g = k2gX2g − kge2X3g
(3)
Similar to the insulin kinetics model, X1g and X2g [mg/kg] are the mass of glucagon in
different compartments. However, X3g [mg/kg] is the mass of glucagon in the plasma. The
variables k1g and k2g [min
−1] are transfer rates between the two compartments, and kge1 and
kge2 [min
−1] are the elimination rates from these compartments. Lastly, ug [mg/(kg·min)] is
the basal infusion rate of glucagon infusion from a pump.
2.4 Glucagon Dynamics
This model shows the relationship between the concentration of glucagon in the plasma and
the endogenous glucose production (EGP) [9]. The equations in the model are shown below:
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Ẏ =




Ż = kgk2gX2g − kgkge2X3g − kcZ
(4)
First, Y [mg/kg] is equal to the effect glucagon has on EGP. The clearance rate of glucagon
from the compartment is given by kc. SfGG [L/(ng·min)] is the patient’s sensitivity to
glucagon. VdGG [L/kg] is glucagon’s volume of distribution. The parameter kg is equal
to the coefficient of X3g in the above equation.
2.5 Carbohydrate Absorption
The carbohydrate absorption model measures the changes in blood glucose caused by the
behavior of insulin and glucagon as well as natural glucose uptake. This nonlinear model
was proposed by Hovorka et al. [6].
Q̇1 = −X2Q1 − F c01 − FR + K12Q2 + UG + EGP0(1 −X3 + Y + kg3Z)
Q̇2 = X1Q1 − k12Q2 −X2Q2
(5)
Q1 and Q2 [mmol/kg] are the masses of glucose in the plasma and compartment, respectively.
EGP0 [mmol/(kg·min)] is the basal endogenous glucose production with an insulin concen-
tration of zero. F c01 is the natural glucose uptake, and FR is the renal glucose clearance rate.
Both of these are given in units of mmol/(kg·min). The variable UG [mmol/(kg·min)] is the








DG is the estimated carbohydrate intake [mmol/kg], AG is the carbohydrate availability




The differential equations were solved numerically using a Runga-Kutta-Fehlberg (RK45)
algorithm programmed into MATLAB. A fourth order Runga-Kutta algorithm is a com-
monly used differential equation solver. However, the RK45 algorithm differentiates itself
by allowing for varied time steps rather than fixed steps [5]. This fact makes the RK45
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algorithm better suited to test the rapid changes in insulin and glucose that occur at the
beginning of the simulation and after meals.
3.2 Patient Generation and Simulation
Many of the parameters in the system were not constants but rather a range of values
that vary based on different biological factors. Because of this, a random value from each
range was assigned to a patient at the beginning of each simulation. This ensured a variety
of patients were tested and the code was not designed to treat one patient better than
another. Through this method, the controller was programmed to treat both patients with
high metabolisms as well as those with low metabolisms.
The patient was then simulated separately from the controller code via a function with insulin
and glucagon injections being passed to the patient throughout the process. However, the
simulation only checked the blood glucose of the patient every five minutes to confirm the
simulation matched the patient. This was done so insulin and glucagon injections were based
on accurate readings rather than simply the simulation’s expected values.
3.3 Controller Design
In order to implement a PID controller, gains had to be determined for each of the three
components. The initial gains were 0.5, 0.05, and 14, respectively. These gains were chosen
for two different reasons. First, the derivative values were on the order of five times smaller
than the proportional component. Thus, it needed a larger gain to give it weight in the
controller. Similarly, the integral component was substantially larger leading to its small
gain. The second reason is that the system has a 20 minute delay between insulin injection
and when it affects glucose levels. Thus, too little insulin being injected immediately after a
meal would lead to too high of a blood sugar while too much insulin after a meal was digested
would lead to a rapid decrease in glucose. Thus, the derivative gain had to be relatively large
while the integral gain needed to be low. Originally, the Ziegler-Nichols tuning method was
to be used in determining these values. This method is commonly used in physical systems
and can be applied to math models. Unfortunately, the method is designed to work with
cyclic functions [2]. The gradual reduction in glucose over time precludes such behavior
though, so another method was proposed.
Once the initial gains were set, the simulation began to progress based on ingested meals and
patient blood sugar readings. After each peak glucose reading from a meal, the simulation
evaluated the expected and actual glucose levels as well as the derivatives of the two during
the rising period. Based on the difference between these values, the proportional and deriva-
tive gains were altered. If the actual glucose was greater than the expected, the proportional
gain was increased. If it was lower, the opposite occurred. The same was done if the actual
derivative did not match with the expected derivative. In addition, if the patient’s glucose
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Before showing how the controller behaved in the patient it is important to gain an un-
derstanding of how the system behaves without outside intervention. Figure 1 shows a
simulation of the system prior to any controller implementation.
Figure 1. A plot of a diabetic’s blood-sugar over time with no insulin
Blood-sugar is measured in mg/dL on the y-axis as per medical standards. This simulation
lasts an entire day starting at 7 A.M. and finishing at the 24 hour mark. A meal was
also administered at 7 AM, 12 PM, and 5 PM. The meals administered were 100 grams of
carbohydrates. As can be seen, the meals cause a rise-time of about two hours prior to a
decline caused by the first term in the Q1 equation in equation set (5). The glucose does
not reach its pre-meal value before another meal is ingested though. Because of this, the
glucose reaches a peak value for the day of about 650 mg/dL following dinner. Despite this,
the body’s lack of ability to produce its own sugar causes a rapid decline afterward which
in turn causes the blood sugar to reach zero before the next morning. The span of time
between peak value and critical condition of the patient is about nine hours.
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When adding the simulation’s expected values to the plot, it was important to ensure ex-
pected values did not diverge from the patient’s actual state. Figure 2 shows an example of
this happening.
Figure 2. A plot showing the diverging of signals
As can be seen above, when the simulation does not fit itself to the glucose of the patient,
the signals diverge. If insulin were to be injected at this point, the simulation would think
a large amount of insulin is needed given its high glucose. However, the patient is in a
healthy range for the majority of this time. Thus, the patient would receive more insulin
than necessary, causing them to reach a glucose level of 0 mg/dL. By sampling the patient’s
blood-sugar the simulation does not risk this occurring. All this must be done because the
parameters of each patient are unknown by the system, as would be the case in a clinic.
4.2 PID Controller Simulations
Following the development of the system, a standard PID controller was programmed to
inject insulin during the simulation. Figure 3 shows the plot of a simulation.
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Figure 3. A plot of insulin treatment via PID controller
This plot has a few interesting attributes when compared to Figure 1. While the three peaks
still occur after the meals, the peaks are much lower than without a controller. Additionally,
the highest peak is the first peak whereas it was the last peak without insulin. This is a
result of insulin still being in the blood stream by the time the patient has another meal.
The remaining insulin then causes clearance of the glucose faster than the preceding meal.
As the simulation continues, the oscillations get smaller even if the peak value remains the
same after meals two and three.
Not all patients will react to the same conditions in the same way though. An example of
this is shown in Figure 4.
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Figure 4. A plot showing another case of insulin treatment
Clearly the outcomes for this patient varied substantially from that of the one shown in Figure
3. By dinner time, the patient has hit a blood glucose of 0 mg/dL. Despite the simulation
continuing on, the patient would not have continued on to eat dinner at this point. Using
the same gains for patients, therefore, would not work as a solution. To account for these
differences, the controller was designed to check expected values against actual values, and
alter its gains to account for these differences.
Once the insulin controller had been developed to account for different patients, the glucagon
controller was developed. Figure 5 shows how the initial glucagon controller functioned.
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Figure 5. A plot with the preliminary glucagon controller
While the oscillations caused by the glucagon controller and insulin controller together are
smaller than that of the insulin controller alone, the oscillations are still larger than desirable.
Given that the body is asleep, it is better to have minor glucose changes to ensure the patient
is not made to feel sick. For this reason, the same types of corrections were made to the
glucagon controller as had been made to the insulin controller.
4.3 Intelligent Controller Simulations
Gains were changed for the insulin controller based on the patient’s reaction to insulin
injections and glucose clearance. Figure 6 is a plot depicting a simulation from the finalized
insulin controller.
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Figure 6. A simulation of glucose with fully functional insulin controller
Glucose levels with the intelligent controller are kept lower during the day than with the
standard PID controller. The same initial gains were used for both the preliminary and
final controllers to better illustrate how the controller’s ability to adjust the gain benefited
the patient. Oscillations in glucose levels are kept in a safer range with this controller as
the glucose is kept closer to 100 mg/dL than before. However, this better management of
glucose results in a zero reading earlier in the evening. This was addressed via the glucagon
controller which is shown in Figure 7.
Figure 7. The final glucagon and insulin controller
Glucose Regulation Using an Intelligent PID Controller 12
As can be seen around the 15 hour mark, the first glucagon injection results in a large
change in glucose on the order of 100 mg/dL. This is similar to the non-intelligent controller.
However, the oscillations quickly shrink and maintain a healthy level through the rest of the
night. This simulation also ended the patient’s glucose at a similar value to where it started
that morning.
5 Future Directions
The simulations were simple to run through MATLAB, but the computational power a
computer can offer is not necessarily standard on all phones and especially not insulin pumps.
Because of this, a less computationally intensive solution needs to be found which also
offers better control and minimizes the fluctuations which occur after meals. One potential
solution is model predictive control [8]. Model predictive control uses optimization software
to minimize the error function before enacting the steps to actual correct this error [4]. This
means the system can run several different simulations to test how different insulin injections
will affect the body. Through this method, the minimal amount of insulin can be injected
while still achieving the best outcome. Despite the simulations being run repetitively, the
optimization algorithm is designed to lessen the computational strain on the device.
Another trend being observed is the development of artificial intelligence in artificial pan-
creases [10]. Artificial intelligence is being used to analyze the results of injections to de-
termine the values of the parameters within the system of equations. By analyzing patient
data over several days, the system can be optimized to achieve the same results as model
predictive control.
6 Conclusion
In order to manage Type I diabetes, insulin must be administered into the body. To ensure an
accurate prediction can be made of how insulin affects glucose, models have been developed
to be used in control algorithms. One potential algorithm uses PID control. Using a PID
control algorithm to administer both insulin and glucagon to a diabetic patient allows the
patient to maintain better glucose levels throughout the day as well as at night. This can
be done by adjusting controller gains as the simulation runs to better match the behavior
of the simulation to that of the patient’s body. However, based on the results found here, it
is possible to improve the algorithm used to keep the patient’s glucose within a smaller and
lower range. This is possible through both model predictive control and artificial intelligence.
Both of these methods are currently being researched and are expected to be used in artificial
pancreases in the near future.
Glucose Regulation Using an Intelligent PID Controller 13
7 References
[1] New CDC report: More than 100 million Americans have diabetes or prediabetes, Jul
2017.
[2] K. Astroem and T. Haegglund. Revisiting the Ziegler-Nichols step response method for
PID control. Journal of Process Control, 14, 2004.
[3] M. Atkinson, G. Eisenbarth, and A. Michels. Type 1 diabetes. The Lancet, 383, 2014.
[4] E. Camacho and C. Alba. Model Predictive Control.
[5] Steven C. Chapra. Applied Numerical Methods with MATLAB for Engineers and Sci-
entists. McGraw-Hill Education, fourth edition, 2018.
[6] R. Hovorka, V. Canonico, L. Chassin, U. Haueter, M. Massi-Benedetti, M. Federici,
T. Pieber, H. Schaller, L. Schaupp, T. Vering, , and M. Wilinska. Nonlinear model
predictive control of gluxose concentration in subjects with type 1 diabetes. IOP Science,
25, 2004.
[7] C. Man, F. Micheletto, D. Lv, M. Breton, and C. Kovatchev, B. amd Cobelli. The
uva/padova type 1 diabetes simulator: New features. Journal of Diabetes Science and
Technology, 2014.
[8] M. Messori, G. Incremona, C. Cobelli, and L. Magni. Individualized model predictive
control for the artificial pancreas: In silico evaluation of closed-loop glucose control.
IEEE Control Systems Magazine, 38, 2018.
[9] N. Resalat, J. Youssef, N. Tyler, J. Castle, and P. Jacobs. A statistical virtual patient
population for the glucoregulatory system in type 1 diabetes with integrated exercise
model. PLOS One, 2019.
[10] T. Zhu, K. Li, and P. Georgiou. A dual-hormone closed-loop delivery system for type 1
diabetes using deep reinforcement learning. The Lancet, 2019.
